Well @MongooseMayhem, I'm not sure if there is a recognised competitor. One of the reasons I have recently bought in to RCE is that there is no standard regimen for burns, so a product that could slot in as standard of care would have an enormous market.
In the billions -- if it could solve the problem of the bugs that live on the skin (like staph a., as in MRSA) having a lot of resistance to the standard first and second line antibiotics.
Ann: Fiona Stanley Hospital Phase I/II Clinical Trial Agreement, page-24
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
-0.010(1.96%) |
Mkt cap ! $115.8M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 55.0¢ | 50.0¢ | $168.7K | 317.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6252 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 13561 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |